newsPhase III trial shows that adults hospitalised for acute heart…
4 March 2022 | By European Pharmaceutical Review
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.